Financials Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/06/2024 BST 5-day change 1st Jan Change
0.6252 USD -8.89% Intraday chart for Quoin Pharmaceuticals, Ltd. -15.51% -87.25%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 15.19 6.884 4.842 2.488 - -
Enterprise Value (EV) 1 15.19 6.884 4.842 2.488 2.488 2.488
P/E ratio -0.34 x -0.36 x -0.51 x -0.18 x -0.67 x -2.78 x
Yield - - - - - -
Capitalization / Revenue - - - - - 0.26 x
EV / Revenue - - - - - 0.26 x
EV / EBITDA - - - - - -
EV / FCF -3,281,594 x - - - - -
FCF Yield -0% - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 55.7 404 987 3,980 - -
Reference price 2 273.0 17.04 4.905 0.6252 0.6252 0.6252
Announcement Date 14/04/22 09/03/23 13/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 9.596
EBITDA - - - - - - -
EBIT 1 - -6.063 -9.258 -9.378 -10.12 -11.24 -9.874
Operating Margin - - - - - - -102.9%
Earnings before Tax (EBT) 1 - -21.46 -9.382 -8.687 -10.46 -11.16 -7.718
Net income 1 -2.095 -21.46 -9.447 -8.687 -7.979 -11.16 -7.718
Net margin - - - - - - -80.43%
EPS 2 -315.0 -813.0 -46.80 -9.640 -3.515 -0.9350 -0.2250
Free Cash Flow - -4.63 - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 16/06/21 14/04/22 09/03/23 13/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -2.981 -2.176 -2.668 -2.328 -2.086 -2.776 -2.26 -2.125 -2.218 - -2.513 -2.563 -2.59
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -11.82 -1.683 -2.668 -3.03 -2.001 -2.603 -2.107 -1.927 -2.05 - -2.581 -2.71 -2.846
Net income 1 -11.82 -1.683 -2.668 -3.095 -2.001 -2.603 -2.107 -1.927 -2.05 - -2.455 -2.515 -2.566
Net margin - - - - - - - - - - - - -
EPS 2 634.5 -30.00 -38.88 -11.28 -4.955 -4.080 -2.130 -1.950 -2.080 - -0.7150 -0.6350 -0.6500
Dividend per Share - - - - - - - - - - - - -
Announcement Date 14/04/22 23/05/22 18/08/22 10/11/22 09/03/23 09/05/23 03/08/23 09/11/23 13/03/24 09/05/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -4.63 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 16/06/21 14/04/22 09/03/23 13/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.6252 USD
Average target price
5.483 USD
Spread / Average Target
+777.05%
Consensus
  1. Stock Market
  2. Equities
  3. QNRX Stock
  4. Financials Quoin Pharmaceuticals, Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW